N-quinoxalin-5-yl-acetamide | 26556-23-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-quinoxalin-5-yl-acetamide
• 英文别名: N-Chinoxalin-5-yl-acetamid；5-Acetamino-chinoxalin；N-quinoxalin-5-ylacetamide
• CAS: 26556-23-0
• 化学式: C₁₀H₉N₃O
• 分子量: 187.201
• InChiKey: BESZIEFHYJYFBL-UHFFFAOYSA-N

物化性质

• 沸点：
  438.7±25.0 °C(Predicted)
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-quinoxalin-5-yl-acetamide 在 硫酸 、 水 作用下， 生成 N-acetyl-sulfanilic acid quinoxalin-5-ylamide
  参考文献：
  名称：

  取代的磺胺喹喔啉; 2-磺胺基氨基喹喔啉的一些衍生物和异构体。

  摘要：

  DOI：

  10.1021/ja01187a082
• 作为产物：
  描述：

  5,6-二硝基-喹喔啉 在 palladium on activated charcoal 、 一水合肼 作用下， 生成 N-quinoxalin-5-yl-acetamide
  参考文献：
  名称：

  490.亲电取代。第十一部分。硫酸中六元氮杂环化合物的硝化

  摘要：

  DOI：

  10.1039/jr9570002521

文献信息

• 567. Quinoxaline N-oxides. Part I. The oxidation of quinoxaline and its Bz-substituted derivatives
  作者：Justus K. Landquist

  DOI：10.1039/jr9530002816

  日期：——
• Substituted 1,10-Phenanthrolines. XI. Aza Derivatives¹
  作者：Francis H. Case、James A. Brennan

  DOI：10.1021/ja01532a046

  日期：1959.12
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20170355705A1

  公开（公告）日：2017-12-14

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES DE L'URÉE SUBSTITUÉS ET PONTÉS EN TANT QUE MODULATEURS DE LA SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079710A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079711A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. (I)